{"id":8602,"date":"2025-02-28T08:19:53","date_gmt":"2025-02-28T06:19:53","guid":{"rendered":"https:\/\/www.norameda.com\/?p=8602"},"modified":"2025-02-25T16:24:44","modified_gmt":"2025-02-25T14:24:44","slug":"noramedas-commitment-to-advancing-rare-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.norameda.com\/en\/noramedas-commitment-to-advancing-rare-disease-treatment\/","title":{"rendered":"Norameda\u2019s Commitment to Advancing Rare Disease Treatment"},"content":{"rendered":"<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Rare diseases present unique challenges in diagnosis, treatment, and patient care. As a company dedicated to improving healthcare, Norameda continues to prioritize rare diseases by expanding its portfolio of innovative medicines and strengthening partnerships with leading medical institutions.<\/span><\/p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Expanding Access to Rare Disease Treatments<\/span><\/b><\/p>\n<p class=\"MsoNormal\">In 2024, Norameda introduced four new treatments for rare diseases, marking a significant milestone in improving patient access to essential therapies. The newly launched medicines address:<\/p>\n<ul>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l1 level1 lfo1;\"><!-- [if !supportLists]--><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Alpha mannosidosis \u2013 a rare genetic disorder affecting lysosomal function<\/span><\/li>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l1 level1 lfo1;\"><span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0<\/span><span lang=\"EN-GB\" style=\"text-indent: -18pt;\">Fabry disease \u2013 a metabolic disorder caused by enzyme deficiency<\/span><\/li>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l1 level1 lfo1;\"><span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0\u00a0<\/span><span lang=\"EN-GB\" style=\"text-indent: -18pt;\">Leber\u2019s hereditary optic neuropathy (LHON) \u2013 a mitochondrial disease leading to vision loss<\/span><\/li>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l1 level1 lfo1;\"><span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0<\/span><span lang=\"EN-GB\" style=\"text-indent: -18pt;\">Narcolepsy \u2013 a neurological condition that affects sleep regulation<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">A key achievement in 2024 was the launch of a new treatment for Fabry disease and the successful representation of Wakix for narcolepsy treatment. These efforts demonstrate Norameda\u2019s commitment to ensuring that patients receive timely and effective treatment options.<\/span><\/p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Lithuania: A Leader in Alpha Mannosidosis Diagnosis<\/span><\/b><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">One of the notable successes in Lithuania\u2019s rare disease landscape is the diagnosis of Alpha mannosidosis. With seven diagnosed cases, Lithuania has exceeded the number of cases identified in the Scandinavian region, highlighting the country\u2019s progress in rare disease diagnostics.<\/span><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Early and accurate diagnosis is crucial for patients with rare diseases, as it enables timely interventions that can significantly improve their quality of life. Lithuania\u2019s achievements in Alpha mannosidosis diagnosis showcase the effectiveness of collaboration between healthcare institutions, diagnostic centers, and pharmaceutical partners.<\/span><\/p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">The Complexity of Rare Disease Care Pathways<\/span><\/b><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Managing rare diseases requires specialized knowledge, multidisciplinary collaboration, and coordinated patient care pathways. The complexity of these conditions means that standard treatment approaches are often insufficient.<\/span><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Recognizing this challenge, the European Union established 24 European Reference Networks (ERNs) in 2017 to facilitate cross-border cooperation in rare disease treatment. The Vilnius Santaros Clinic has actively participated in these networks, contributing to knowledge-sharing and best practices in rare disease management.<\/span><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Norameda plays a crucial role in streamlining care pathways, ensuring that patients receive integrated and high-quality treatment. By fostering collaboration between healthcare professionals, patient advocacy groups, and research institutions, Norameda aims to improve outcomes for individuals affected by rare diseases.<\/span><\/p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Driving Innovation and Knowledge Exchange<\/span><\/b><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">As a leading pharmaceutical company, Norameda is dedicated to advancing medical innovation and fostering international collaboration. By supporting the Rare Diseases Coordination Centre at Vilnius Santaros Clinic, Norameda contributes to groundbreaking research, educational initiatives, and improved patient access to life-changing treatments.<\/span><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">The company\u2019s long-term vision includes:<\/span><\/p>\n<ul>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo2;\"><span lang=\"EN-GB\" style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"><span style=\"mso-list: Ignore;\"><span style=\"font: 7.0pt 'Times New Roman';\">\u00a0<\/span><\/span><\/span><!--[endif]--><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Expanding treatment options for rare diseases<\/span><\/li>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo2;\"><span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0<\/span><span lang=\"EN-GB\" style=\"text-indent: -18pt;\">Enhancing diagnostic capabilities through strategic partnerships<\/span><\/li>\n<li class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo2;\"><span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-size-adjust: none; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-variant-emoji: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';\">\u00a0<\/span><span lang=\"EN-GB\" style=\"text-indent: -18pt;\">Promoting cross-border collaboration to share best practices in patient care<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">A Future of Better Care for Rare Disease Patients<\/span><\/b><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">The journey toward better rare disease treatment requires continuous innovation, strong partnerships, and a commitment to patient well-being. Norameda remains at the forefront of this mission, ensuring that patients with rare conditions receive the care they deserve.<\/span><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">By facilitating access to new therapies, supporting diagnostic advancements, and moderating knowledge exchange between countries, Norameda is shaping the future of rare disease management in Lithuania and beyond.<\/span><\/p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"mso-ansi-language: EN-GB;\">Together, we can make a lasting impact.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rare diseases present unique challenges in diagnosis, treatment, and patient care. As a company dedicated to improving healthcare, Norameda continues to prioritize rare diseases by expanding its portfolio of innovative medicines and strengthening partnerships with leading medical institutions. Expanding Access to Rare Disease Treatments In 2024, Norameda introduced four new treatments for rare diseases, marking [&hellip;]<\/p>\n","protected":false},"author":220,"featured_media":8603,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_links_to":"","_links_to_target":""},"categories":[136],"tags":[],"_links":{"self":[{"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/posts\/8602"}],"collection":[{"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/users\/220"}],"replies":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/comments?post=8602"}],"version-history":[{"count":1,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/posts\/8602\/revisions"}],"predecessor-version":[{"id":8608,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/posts\/8602\/revisions\/8608"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/media\/8603"}],"wp:attachment":[{"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/media?parent=8602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/categories?post=8602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.norameda.com\/en\/wp-json\/wp\/v2\/tags?post=8602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}